Article

Poor Nutrition at Age 3 and Schizotypal Personality at Age 23: The Mediating Role of Age 11 Cognitive Functioning

William Penn University, Filadelfia, Pennsylvania, United States
American Journal of Psychiatry (Impact Factor: 14.72). 07/2012; 169(8):822-30. DOI: 10.1176/appi.ajp.2012.11081173
Source: PubMed

ABSTRACT Poor prenatal nutrition has been associated with schizophrenia spectrum disorders in the Netherlands and China, and it has been suggested that perinatal and postnatal nutritional factors lead to the development of schizophrenia and the exhibition of schizotypal traits later in life. There appears to be no prior research on the existence of possible factors that may mediate the relationship between malnutrition and schizophrenia spectrum disorders or whether this association is a direct one. The authors tested the hypothesis that low IQ mediates the relationship between early childhood malnutrition and adult schizotypal personality.
Participants were drawn from a birth cohort of 1,795 boys and girls who were followed prospectively. Objective indicators of malnutrition (anemia and stunting) were assessed at age 3. Verbal and performance intelligence were assessed at age 11, and schizotypal personality was assessed at age 23.
Both stunting and anemia at age 3 were associated with low IQ at age 11. Low performance IQ at age 11 was associated with increased interpersonal and disorganized features of schizotypal personality at age 23. Poor performance IQ was found to mediate the relationship between poor nutrition at age 3 and interpersonal and disorganized features of schizotypy at age 23. Findings in female participants were replicated in male participants.
Given that poor nutrition is an alterable risk factor, these findings suggest that nutritional enhancements may improve brain functioning and possibly reduce some features of schizotypal personality disorder.

2 Bookmarks
 · 
92 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Early insults during critical periods of brain development, both prenatal and postnatal, can result in epigenetic changes that may impact health and behavioral outcomes over the life span and into future generations. There is ample evidence that these early stages of brain development are sensitive to various environmental insults, including malnutrition, childhood trauma, and drug exposures. The notion that such changes, both physiological and behavioral, can also carry over into subsequent generations has long been recognized, especially in the context of experimental studies. However, epigenetic mechanisms capable of explaining such phenomena were not available until relatively recently, with most of this research published only within the last decade.
    Progress in molecular biology and translational science 01/2014; 128:177-98. DOI:10.1016/B978-0-12-800977-2.00007-3 · 3.11 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Schizophrenia is associated with excess physical comorbidity. Yet, to our knowledge, large studies are lacking on the associations with somatic diseases before the onset of schizophrenia. The authors conducted a nationwide study of the full spectrum of treated somatic diseases before the first diagnosis of schizophrenia.
    Schizophrenia Bulletin 07/2014; DOI:10.1093/schbul/sbu110 · 8.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Individuals with schizotypal personality disorder (SPD) often present with cognitive impairment similar, but of a lesser magnitude to, what is seen in schizophrenia. Cognitive dysfunction combined with social and perceptual disturbances, which are the hallmarks of this disorder, are directly related to substantially lower functioning. There is no FDA-approved medication for cognitive deficits in SPD; however, potential agents, including α2a and dopamine agonists, are under investigation. Cognitive remediation therapy (CRT) is a behavioral treatment that has been shown to improve cognitive and psychosocial functioning in individuals with schizophrenia. Application of CRT in this population is novel and more large-scale studies are needed, but this treatment holds promise for the cognitive and social deficits of SPD. There may be a synergy between cognitive remediation and cognitive enhancers such as the α2a agonist guanfacine; research in this area is nascent. Lifestyle modifications such as the use of memory aids, planners, and structured schedules, as well as exercise, may be beneficial for cognitive functioning in this population. Additionally, social skills training in a psychotherapeutic setting can be helpful. Patients frequently present with comorbid mood and anxiety symptoms, and standard SSRI treatment to ameliorate symptoms can have a positive secondary effect on cognitive functioning. For the patient with psychotic-like features, treatment with atypical antipsychotics may also improve overall functioning.
    12/2014; 1(4). DOI:10.1007/s40501-014-0027-0